JCI Editorial Board potential conflicts of interest

First tier

Abbvie Pharmaceutical (T.M. Dawson, J.D. Powell, B.H. Park)

Aduro Biotech (E.M. Jaffee)

Agenus (M. Maus)

American Gene Technologies International (T. Dawson)

Amgen (E.M. Jaffee)

Annexon (P.A. Calabresi)

Apellis Pharmaceuticals (M. Wills-Karp)

Ardelyx (M. Donowitz)

Armis Biopharma Inc. (W. Nelson)

AstraZeneca (E.M. Jaffee, J. Schneck)

Bainum Foundation (F.R. D’Alessio)

Biogen (P.A. Calabresi)

BluebirdBio (J.D. Powell)

Blueone Biosciences (M. Laiho)

Brahm Astra Therapeutics (W. Nelson)

Bristol-Myers Squibb (E.M. Jaffee, J.D. Powell, J. Schneck)

Celgene Corp. (A.P. Feinberg, W. Nelson)

Cepheid Inc. (A.M. De Marzo, W. Nelson)

Corvus (E.M. Jaffee)

CRISPR Therapeutics (M.V. Maus)

Digital Harmonics (W. Nelson)

Disarm Therapeutics (P.A. Calabresi)

Domicell LLC (G.F. Tomaselli, R.G. Weiss)

Dong-A ST (T.M. Dawson)

Dracen Pharmaceuticals (M.R. Horton, J.D. Powell)

DragonFly (E.M. Jaffee)

Eli Lilly (B.H. Park)

Emulate Inc. (M. Donowitz)

Essa Pharma (W.R. Bishai)

Expansion Therapeutics (J.D. Rothstein)

Foundation Medicine (B.H. Park)

Genocea (E.M. Jaffee)

GlaxoSmithKline (J.D. Rothstein)

Hertix (E.M. Jaffee)

HIF Therapeutics (A.S. Sodhi)

Hopstem (T.M. Dawson)

Inhibikase Therapeutics (T.M. Dawson)

Ionis Pharmaceuticals (S.I. Taylor)

Janssen (A.M. De Marzo)

Johnson & Johnson (A.P. Feinberg)

Kite Pharma (M.V. Maus)

Loxo Oncology (B.H. Park)

MDxHealth Inc. (W. Nelson)

MedImmune (P.A. Calabresi, M.J. Kaplan)

miDiagnostics (S.C. Ray)

Mitokinin (T.M. Dawson)

Neuraly (T.M. Dawson)

NexImmune (J. Schneck)

Pfizer (W. Nelson, B.H. Park)

Procter & Gamble (A.P. Feinberg)

ProQuest Investments (W. Nelson)

Quadrigia (J.D. Powell)

Sanofi (P.A. Calabresi)

Sun Pharma Advanced Research (T.M. Dawson)

Takeda Oncology (M.V. Maus)

TCR2 (M.V. Maus)

Teva Pharmaceuticals (W. Nelson)

Thermo Fisher (A.P. Feinberg)

UD-GenoMed Medical Genomic Technologies (L. Nagy)

Viking (W.R. Bishai)

WindMIL (M.V. Maus)